Company announcement No. 15 / 2026 Zealand Pharma – Execution framework for share buy-back program Copenhagen, Denmark, May 7, 2026 – Zealand Pharma A/S (“the Company” or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced that it has decided to initiate a share buy-back program (the “Program”) in accordance with company announcement no. 13 / 2026. This regulatory update summarizes the execution framework of the Program, to which the following terms apply: The Program will be implemented in accordance with Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe Harbour Regulation”). The Company has appointed Danske Bank as lead manager for the Program. Danske Bank...

Lochem, 7 May 2026 Trading update Q1 2026Volume growth and strong profitability continuePieter Wolleswinkel, CEO ForFarmers: “We started the year with another strong quarter. Acquisitions contributed to positive volume development. Volumes have also remained at a solid level on a like-for-like basis, despite the impact of buy-out schemes and animal diseases. We further strengthened our market positions and once again achieved solid growth in profitability. We have obtained shareholder approval to enter into a joint venture with KPS in Poland. Pending approval from the Polish competition authority, we are on track to complete the transaction in the third quarter.Although current geopolitical developments are creating uncertainty and driving up the prices of raw materials and energy, we are still able—thanks in part to targeted risk management—to...

PathAI’s best-in-class Image Management System (IMS) with advanced AI analysis and workflow capabilities will complement Roche’s digital pathology portfolio to drive laboratory efficiency Combining Roche’s strong position in companion diagnostics and PathAI’s advanced AI platform helps accelerate clinical therapy development, foster the discovery of new biomarkers and create novel diagnostic tools These integrated capabilities will accelerate the shift from broad intervention toward personalised healthcare for patientsBasel, 7 May 2026  – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it has entered into a definitive merger agreement to acquire PathAI, a US-based company in digital pathology and AI-powered technology for pathology laboratories and the biopharma industry. This acquisition builds on the successful...

Company announcement No. 13 / 2026 Zealand Pharma initiates USD 200 million / DKK 1.3 billion share buy-back programRobust cash position of USD 2.3 billion (DKK 14.5 billion) as of March 31, 2026 Financial strength to be further enhanced by significant milestone payments of USD 700 million from Roche in 2026 Continuing to invest significantly in research capabilities to build a leading metabolic health pipeline and execute on Metabolic Frontier 2030 strategyCopenhagen, Denmark, May 7, 2026 – Zealand Pharma A/S (“the Company” or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces that it has decided to initiate a share buy-back program (the “Program”), under which the Company will buy back own shares for a maximum total consideration of...

SCOTTSDALE, Ariz., May 06, 2026 (GLOBE NEWSWIRE) — ON Semiconductor Corporation (Nasdaq: ON) (“onsemi”) announced today the pricing of its private offering of $1.3 billion aggregate principal amount of 0% Convertible Senior Notes due 2031 (the “notes”) at an approximately 52.5% premium to the closing price of onsemi’s common stock on May 6, 2026 of $105.77 per share. The notes were offered only to persons reasonably believed to be qualified institutional buyers in accordance with Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). onsemi has granted to the initial purchasers of the notes an option to purchase, within a 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional $200.0 million aggregate principal amount of the notes. The offering of the notes...

OCEANSIDE, Calif., May 07, 2026 (GLOBE NEWSWIRE) — Suja Life, Inc. today announced the pricing of its initial public offering of 8,888,889 shares of its Class A common stock (“Class A Common Stock”) which are being offered by Suja Life as described in the registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission (the “SEC”), at a public offering price of $21.00 per share. Suja Life has granted the underwriters a 30-day option to purchase up to an additional 1,333,333 shares of Class A Common Stock at the initial public offering price, less the underwriting discounts and commissions. The shares are expected to begin trading on The Nasdaq Global Select Market on May 7, 2026 under the ticker symbol “SUJA.” The offering is expected to close on May 8, 2026 subject to customary closing conditions. Upon...

SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the pricing of an underwritten public offering of 9,859,155 shares of its common stock at a price to the public of $71.00 per share, before underwriting discounts and commissions. The gross proceeds to Cytokinetics from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Cytokinetics, are expected to be approximately $700 million. The offering is expected to close on May 8, 2026, subject to customary closing conditions. Additionally, Cytokinetics has granted the underwriters a 30-day option to purchase up to an additional 1,478,873 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common...

BEIJING, May 06, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application to initiate a clinical trial of its novel CDH17 targeted ADC, ICP-B208. CDH17 is a calcium-dependent cell adhesion protein that plays a key role in tumor cell proliferation, migration, and metastasis. Its tumor-restricted expression and functional role in cancer biology make CDH17 an attractive and differentiated target for ADC therapy, which can be developed for the treatment of gastrointestinal cancers, including colorectal, gastric, pancreatic ductal adenocarcinoma, and biliary...